drugset / Trial / NCT01060137

Fentanyl Matrix in Lung Cancer Pain

NCT01060137 ↗

Phase 4 Completed 268 enrolled Janssen Korea, Ltd., Korea
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the usefulness of fentanyl matrix by assessing patients' satisfaction when administrating fentanyl matrix, a background pain treatment, and a breakthrough pain treatment to lung cancer patients who complain of pain. Fentanyl matrix is designed to deliver medication at a nearly constant amount per unit time into the body through the skin for 3 days (72 hours).

Timeline

Start
2006-05
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 12.5 ug Other
Subject Fentanyl Other / unclassified 25 ug Other

Indications